Watch Live

Tweet TWEET

NeoGenomics Revises Upward its Quarter 3 2013 Guidance

            NeoGenomics Revises Upward its Quarter 3 2013 Guidance

PR Newswire

FT. MYERS, Fla., Sept. 26, 2013

FT. MYERS, Fla., Sept. 26, 2013 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ:
NEO) announced today that it was revising upward its previously issued
guidance for Quarter 3, 2013. The Company now expects revenue of
approximately $16.6 - $16.9 million and earnings per share of $0.01 - $0.02 in
the third quarter. The Company had originally guided to revenue of $15.8 -
$16.4 million and earnings per share of $0.00 - $0.01 on July 31, 2013.

Doug VanOort, the Company's Chairman and CEO, commented, "We experienced
strong year-over-year revenue growth in July and August, and our rate of
growth has continued to accelerate in September. This growth is broad-based,
and is the result of a variety of growth initiatives we have made over the
last eighteen months, including, but not limited to, increasing sales force
productivity and various new product launches. We are scheduled to release
our full third quarter financial results on October 23, 2013."

The Company reserves the right to adjust this guidance at any time based on
the ongoing execution of its business plan. Current and prospective investors
are encouraged to perform their own due diligence before buying or selling any
of the Company's securities, and are reminded that the foregoing estimates
should not be construed as a guarantee of future performance.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that
specializes in cancer genetics diagnostic testing, the fastest growing segment
of the laboratory industry. The company's testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, anatomic pathology and molecular genetic testing.
Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,
Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of
pathologists, oncologists, other clinicians and hospitals throughout the
United States. For additional information about NeoGenomics, visit
http://www.neogenomics.com.

Interested parties can also access investor relations material from Hawk
Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from
Zack's Investment Research at http://www.zacks.com or scr@zacks.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements, Actual results could differ materially from
such statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company's ability to continue gaining
new customers, offer new types of tests, and otherwise implement its business
plan. As a result, this press release should be read in conjunction with the
company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Website: http://www.neogenomics.com
Contact: NeoGenomics, Inc., Steven C. Jones, Director of Investor Relations,
(239) 325-2001, sjones@neogenomics.com; Hawk Associates, Inc., Ms. Julie
Marshall, (305)-451-1888, (212) 825-3210, neogenomics@hawkassociates.com